stockrow
Friday 6 November 2026
Export RVTY’s income statement to Excel — free account
Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
157.75
6.92
+4.59%
Follow RVTY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
3.23% | 3.23% | 3.21% | 0.00% | |
Piotroski F-Score |
6 | 6 | 6 | — | |
| 1.96% | 1.97% | 1.95% | 2.14% | ||
ROIC |
2.33% | 2.36% | 2.38% | 2.50% | |
Return on Tangible Assets |
17.38% | 17.68% | 16.08% | 15.72% | |
Average Days of Receivables |
95.17 | 86.95 | 88.90 | 85.28 | |
Free Cash Flow per Share |
4.37 | 4.49 | 5.11 | 0.00 | |
Free Cash Flow |
509.41 | 501.70 | 570.15 | 602.51 | |
Capital Expenditures |
(73.52) | (68.31) | (57.48) | (53.33) | |
| Other line items | |||||
Cash ROIC |
4.47% | 4.46% | 4.98% | 5.74% | |
Accounts Receivable Turnover |
4.15 | 4.44 | 4.25 | 4.30 | |
Accounts Payable Turnover |
7.32 | 7.63 | 7.62 | 7.65 | |
Inventory Turnover |
3.46 | 3.45 | 3.42 | 3.37 | |
Average Days of Payables |
52.41 | 46.71 | 46.14 | 45.95 | |
Days of Inventory on Hand |
107.24 | 106.67 | 105.38 | 109.43 | |
Tax Rate |
(0.11) | (0.10) | (0.09) | (0.11) | |
Research and Development Expense of Revenue |
7.56% | 7.58% | 7.41% | 7.25% | |
Selling, General and Administrative Expense of Revenue |
34.73% | 34.32% | 35.24% | 36.02% | |
Share Based Compensation of Revenue |
0.80% | 0.82% | 0.84% | 0.85% | |
Interest Coverage |
4.04 | 3.82 | 3.66 | 4.01 | |
Operating CF/Net income |
2.42 | 2.38 | 2.64 | 2.59 | |
Depreciation/Fixed assets |
0.86 | 0.90 | 0.91 | 0.93 | |
Capex/Depreciation |
(0.18) | (0.16) | (0.14) | (0.13) | |
Revenue per Share |
24.51 | 25.95 | 26.10 | 0.00 | |
Operating CF per Share |
5.00 | 5.10 | 5.62 | 0.00 | |
Capex per Share |
(0.63) | (0.61) | (0.52) | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026